Volume 11 Issue 2
Mar.  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(2): 240-246
Cheng Haoyu, Yang Yixin, Yang Fan, et al. Analysis of the efficacy of pretreatment regimen containing idarubicin in allogeneic hematopoietic stem cell transplantation for high-risk refractory leukemia[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 240-246. doi: 10.3969/j.issn.1674-7445.2020.02.009
Citation: Cheng Haoyu, Yang Yixin, Yang Fan, et al. Analysis of the efficacy of pretreatment regimen containing idarubicin in allogeneic hematopoietic stem cell transplantation for high-risk refractory leukemia[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 240-246. doi: 10.3969/j.issn.1674-7445.2020.02.009
shu

Analysis of the efficacy of pretreatment regimen containing idarubicin in allogeneic hematopoietic stem cell transplantation for high-risk refractory leukemia

doi: 10.3969/j.issn.1674-7445.2020.02.009

  • Department of Hematology, Aerospace Center Hospital, Beijing 100049, China

More Information
  • Corresponding author: Wang Jingbo, Email: dpwangjingbo@vip.sina.com
  • Received Date: 2019-12-15
    Available Online: 2021-01-19
  • Publish Date: 2020-03-15
    Abstract
  •   Objective  To investigate the clinical efficacy of pretreatment regimen containing idarubicin (IDA) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-risk refractory leukemia.  Methods  A total of 116 patients with high-risk refractory leukemia who received allo-HSCT treated with 7 types of IDA-containing pretreatment regimes were enrolled in this study. The implantation rate of 116 recipients was summed up. The 2-year overall survival (OS), 2-year disease free survival (DFS), cumulative recurrence rate, recurrent mortality, transplantation related mortality (TRM), cumulative incidence of acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD) were statistically analyzed by Kaplan-Meier survival curve.  Results  All 116 recipients successfully implanted. The median follow-up time was 28 (7-70) months. Among them, 64 recipients survived, the 2-year OS was 55.2%, 2-year DFS was 51.7%, 2-year recurrent mortality was 23.3% and 2-year TRM was 18.1%. Among 116 recipients, 72 cases suffered from aGVHD. The 2-year cumulative incidence rate of aGVHD was 62.1% including 20 cases of grade Ⅲ-Ⅳ aGVHD, the 2-year cumulative incidence rate was 17.2%. Among 116 recipients, 59 cases presented with cGVHD. The 2-year cumulative incidence rate was 55.4%, of which the 2-year cumulative incidence rate of extensive cGVHD was 14.7%. Among 116 recipients, 30 cases recurred with a 2-year cumulative recurrence rate of 25.9%.  Conclusions  IDA-containingpretreatment regime has high safety and effectiveness, and can be used as an effective pretreatment regime for transplantation preprocessing in patients with high-risk refractory leukemia.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    中华医学会血液学分会白血病淋巴瘤学组.复发难治性急性髓系白血病中国诊疗指南(2017年版)[J].中华血液学杂志, 2017, 38(3):183-184. DOI: 10.3760/cma.j.issn.0253-2727.2017.03.002.

    Leukemia & Lymphoma Group in Branch of Hematology of Chinese Medical Association. The guidelines for diagnosis and treatment of acute myelogenous leukemia(relapse/refractory) in China (2017)[J]. Chin J Hematol, 2017, 38(3):183-184. DOI:10.3760/cma.j.issn. 0253-2727.2017.03.002.
    [2]
    KOBAYASHI H. Treatment of relapsed or refractory acute myeloid leukemia[J]. Rinsho Ketsueki, 2017, 58(10):1895-1904. DOI: 10.11406/rinketsu.58.1895.
    [3]
    SORROR ML. How I assess comorbidities before hematopoietic cell transplantation[J]. Blood, 2013, 121(15):2854-2863. DOI: 10.1182/blood-2012-09-455063.
    [4]
    MO XD, KONG J, ZHAO T, et al. Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes[J]. Biol Blood Marrow Transplant, 2014, 20(12):2023-2028. DOI: 10.1016/j.bbmt.2014.08.023.
    [5]
    WANG J, ZHAO J, FEI X, et al. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia[J]. Medicine (Baltimore), 2018, 97(17):e0228. DOI: 10.1097/MD.0000000000010228.
    [6]
    中华医学会血液学分会干细胞应用学组.中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅱ)——移植后白血病复发(2016年版)[J].中华血液学杂志, 2016, 37(10):846-851.DOI:10.3760/cma.j.issn. 0253-2727.2016.10.004.

    Stem Cell Application Group in Branch of Hematology of Chinese Medical Association. The consensus of allogeneic hematopoietic transplantation for hematological diseases in China (Ⅱ): post-transplant leukemia relapse (2016)[J]. Chin J Hematol, 2016, 37(10):846-851.DOI: 10.3760/cma.j.issn.0253-2727.2016.10.004.
    [7]
    张利宁, 陈欣, 冯四洲, 等.异基因造血干细胞移植治疗复发难治急性髓系白血病研究进展[J].白血病·淋巴瘤, 2018, 27(7):444-448.DOI:10.3760/cma.j.issn. 1009-9921.2018.07.019.

    ZHANG LN, CHEN X, FENG SZ, et al. Progress of allogeneic hematopoietic stem cell transplantation in treatment of relapsed refractory acute myeloid leukemia[J]. J Leuk Lymphoma, 2018, 27(7):444-448.DOI: 10.3760/cma.j.issn.1009-9921.2018.07.019.
    [8]
    VAN DEN BRINK MR, PORTER DL, GIRALT S, et al. Relapse after allogeneic hematopoietic cell therapy[J]. Biol Blood Marrow Transplant, 2010, 16(Suppl 1):S138- S145. DOI: 10.1016/j.bbmt.2009.10.023.
    [9]
    ALYEA EP, KIM HT, HO V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome[J]. Biol Blood Marrow Transplant, 2006, 12(10):1047-1055. doi: 10.1016/j.bbmt.2006.06.003
    [10]
    刘微, 李渊, 邱志祥, 等. FLAG序贯马利兰/环磷酰胺预处理方案对异基因造血干细胞移植治疗难治/复发性急性髓系白血病疗效影响的临床观察[J].中华内科杂志, 2018, 57(8):576-581.DOI:10.3760/cma.j.issn. 0578-1426.2018.08.008.

    LIU W, LI Y, QIU ZX, et al. Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide pretreatment regimen for refractory/relapsed acute myeloid leukemia[J]. Chin J Intern Med, 2018, 57(8):576-581.DOI: 10.3760/cma.j.issn.0578-1426.2018.08.008.
    [11]
    ZHANG R, LU X, WANG H, et al. Idarubicin-intensified hematopoietic cell transplantation improves relapse and survival of high-risk acute leukemia patients with minimal residual disease[J]. Biol Blood Marrow Transplant, 2019, 25(1):47-55. DOI: 10.1016/j.bbmt.2018.07.021.
    [12]
    苏秀华, 姚剑峰, 张桂新, 等.异基因造血干细胞移植治疗难治/复发急性髓系白血病的疗效及预后因素分析[J].中华血液学杂志, 2017, 38(12):1024-1030. DOI: 10.3760/cma.j.issn.0253-2727.2017.12.004.

    SU XH, YAO JF, ZHANG GX, et al. Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors[J]. Chin J Hematol, 2017, 38(12):1024-1030. DOI:10.3760/cma.j.issn. 0253-2727.2017.12.004.
    [13]
    TANG W, FAN X, WANG L, et al. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study[J]. Medicine (Baltimore), 2015, 94(15):e706. DOI: 10.1097/MD.0000000000000706.
    [14]
    DOPPELHAMMER M, FRACCAROLI A, PREVALSEK D, et al. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis[J]. Ann Hematol, 2019, 98(3):753-762. DOI: 10.1007/s00277-019-03593-2.
    [15]
    HOCHBERG J, ZAHLER S, GEYER MB, et al. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia[J]. Bone Marrow Transplant, 2019, 54(2):226-235. DOI: 10.1038/s41409-018-0247-9.
    [16]
    HONG M, WU Q, HU C, et al. Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis[J]. Bone Marrow Transplant, 2012, 47(2):196-202. DOI: 10.1038/bmt.2011.66.
    [17]
    FANG J, ZHANG R, WANG H, et al. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective comparative study[J]. Leuk Res, 2016, 46:61-68. DOI: 10.1016/j.leukres.2016.04.014.
    [18]
    MARKS DI, KEBRIAEI P, STELLJES M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia[J]. Biol Blood Marrow Transplant, 2019, 25(9):1720-1729. DOI: 10.1016/j.bbmt. 2019.04.020.
    [19]
    KEBRIAEI P, STELLJE M, DEANGELO DJ, et al. Role of remission status and prior transplant in optimizing survival outcomes following allogeneic hematopoietic stem transplantation (HSCT) in patients who received inotuzumab ozogamicin for relapsed/refractory(R/R) acute lymphoblastic leukemia(ALL)[J]. Biol Blood Marrow Transplant, 2018, 24(3):S79-S80.DOI: 10.1016/j.bbmt.2017.12.622.
    [20]
    孙于谦, 黄晓军.复发白血病异基因造血干细胞移植后疗效的改进策略[J].中华血液学杂志, 2017, 38(8):732-736. DOI: 10.3760/cma.j.issn.0253-2727.2017.08.018.

    SUN YX, HUANG XJ. Strategies for improving the outcomes of allogeneic stem cell transplantation in patients with relapsed acute leukemia[J]. Chin J Hematol, 2017, 38(8):732-736. DOI:10.3760/cma.j.issn.0253-2727. 2017.08.018.
    [21]
    BOSE P, VACHHANI P, CORTES JE. Treatment of relapsed/refractory acute myeloid leukemia[J]. Curr Treat Options Oncol, 2017, 18(3):17. DOI: 10.1007/s11864-017-0456-2.
    [22]
    CUI L, LIU Y, PANG Y, et al. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia[J]. Cancer Gene Ther, 2020, 27(1/2):1-14. DOI: 10.1038/s41417-019-0119-5.
    [23]
    LOTFI K, ZACKRISSON AL, PETERSON C. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance[J]. Cancer Lett, 2002, 178(2):141-149. doi: 10.1016/S0304-3835(01)00824-2
    [24]
    MUUS P, DONNELLY P, SCHATTENBERG A, et al. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent[J]. Semin Oncol, 1993, 20(6 Suppl 8):47-52. http://www.ncbi.nlm.nih.gov/pubmed/8290971
    [25]
    SPETH PA, MINDERMAN H, HAANEN C. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies[J]. Semin Oncol, 1989, 16(1 Suppl 2):2-9. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/104345429000700307
    [26]
    CASTAGNA L, SARINA B, BRAMANTI S, et al. Donor lymphocyte infusion after allogeneic stem cell transplantation[J]. Transfus Apher Sci, 2016, 54(3):345-355. DOI: 10.1016/j.transci.2016.05.011.
    [27]
    GOLDSMITH SR, SLADE M, DIPERSIO JF, et al. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy[J]. Bone Marrow Transplant, 2017, 52(12):1623-1628. DOI: 10.1038/bmt.2017.193.
    [28]
    ORTI G, BARBA P, FOX L, et al. Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect[J]. Exp Hematol, 2017, 48:1-11. DOI: 10.1016/j.exphem.2016.12.004.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (266) PDF downloads(12) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return